116 related articles for article (PubMed ID: 33068301)
1. Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control.
Mohsen M; Elberry AA; Mohamed Rabea A; Abdelrahim MEA; Hussein RRS
Int J Clin Pract; 2021 Mar; 75(3):e13769. PubMed ID: 33068301
[TBL] [Abstract][Full Text] [Related]
2. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
3. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Mosenzon O; Leibowitz G; Bhatt DL; Cahn A; Hirshberg B; Wei C; Im K; Rozenberg A; Yanuv I; Stahre C; Ray KK; Iqbal N; Braunwald E; Scirica BM; Raz I
Diabetes Care; 2017 Jan; 40(1):69-76. PubMed ID: 27797925
[TBL] [Abstract][Full Text] [Related]
4. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
Heerspink HJ; Johnsson E; Gause-Nilsson I; Cain VA; Sjöström CD
Diabetes Obes Metab; 2016 Jun; 18(6):590-7. PubMed ID: 26936519
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.
Groop PH; Cooper ME; Perkovic V; Emser A; Woerle HJ; von Eynatten M
Diabetes Care; 2013 Nov; 36(11):3460-8. PubMed ID: 24026560
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Groop PH; Cooper ME; Perkovic V; Hocher B; Kanasaki K; Haneda M; Schernthaner G; Sharma K; Stanton RC; Toto R; Cescutti J; Gordat M; Meinicke T; Koitka-Weber A; Thiemann S; von Eynatten M
Diabetes Obes Metab; 2017 Nov; 19(11):1610-1619. PubMed ID: 28636754
[TBL] [Abstract][Full Text] [Related]
8. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
[TBL] [Abstract][Full Text] [Related]
9. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
10. A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy.
Mohsen M; Elberry AA; Rabea AM; Khalil DM; Abdelrahim MEA; Hussein RRS
Can J Diabetes; 2022 Mar; 46(2):134-141.e2. PubMed ID: 35181219
[TBL] [Abstract][Full Text] [Related]
11. Saxagliptin attenuates glomerular podocyte injury by increasing the expression of renal nephrin and podocin in type 2 diabetic rats.
Hu Y; Ye S; Xing Y; Lv L; Hu W; Zhou W
Acta Diabetol; 2020 Mar; 57(3):279-286. PubMed ID: 31535208
[TBL] [Abstract][Full Text] [Related]
12. Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study.
Apperloo EM; Pena MJ; de Zeeuw D; Denig P; Heerspink HJL
Diabetes Obes Metab; 2018 Jun; 20(6):1377-1383. PubMed ID: 29345404
[TBL] [Abstract][Full Text] [Related]
13. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Sharma AK; Kanawat DS; Mishra A; Dhakad PK; Sharma P; Srivastava V; Joshi S; Joshi M; Raikwar SK; Kurmi MK; Srinivasan BP
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
[TBL] [Abstract][Full Text] [Related]
14. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.
Scirica BM; Mosenzon O; Bhatt DL; Udell JA; Steg PG; McGuire DK; Im K; Kanevsky E; Stahre C; Sjöstrand M; Raz I; Braunwald E
JAMA Cardiol; 2018 Feb; 3(2):155-163. PubMed ID: 29214305
[TBL] [Abstract][Full Text] [Related]
16. Nephroprotection with saxagliptin.
Iazzetta N; Garofalo C; Savino M; Sagliocca A; Santangelo S; Pacilio M; Liberti ME; Camocardi A; Ambrosca C; Minutolo R; De Nicola L; Conte G
G Ital Nefrol; 2015; 32(6):. PubMed ID: 26845214
[TBL] [Abstract][Full Text] [Related]
17. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
[TBL] [Abstract][Full Text] [Related]
18. Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2013 Dec; 13(6):443-50. PubMed ID: 23990203
[TBL] [Abstract][Full Text] [Related]
19. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study.
Goldshtein I; Karasik A; Melzer-Cohen C; Engel SS; Yu S; Sharon O; Brodovicz K; Gadir N; Katzeff HL; Radican L; Chodick G; Shalev V; Tunceli K
J Diabetes Complications; 2016; 30(7):1354-9. PubMed ID: 27320183
[TBL] [Abstract][Full Text] [Related]
20. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
